Cyclandelate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317569

CAS#: 456-59-7

Description: Cyclandelate is a direct-acting smooth muscle relaxant vasodilator used in the treatment of claudication, arteriosclerosis and Raynaud's disease. It is also used to treat nighttime leg cramps, and has been investigated for its effect against migraine. It is orally administered.

Chemical Structure

img
Cyclandelate
CAS# 456-59-7
Instruction

Theoretical Analysis

MedKoo Cat#: 317569
Name: Cyclandelate
CAS#: 456-59-7
Chemical Formula: C17H24O3
Exact Mass: 276.17
Molecular Weight: 276.370
Elemental Analysis: C, 73.88; H, 8.75; O, 17.37

Price and Availability

Size Price Availability Quantity
2g USD 150
5g USD 250
10g USD 450
20g USD 850
50g USD 1450
Bulk inquiry

Synonym: Cyclandelate; Cyclospasmol; Capilan; Ciclospasmol; Spasmocyclon; Spasmocyclone;

IUPAC/Chemical Name: (3,3,5-trimethylcyclohexyl) 2-hydroxy-2-phenylacetate

InChi Key: WZHCOOQXZCIUNC-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3

SMILES Code: CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O

Appearance: White to off-white solid powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 276.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Diener HC, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. Cephalalgia. 2001 Feb;21(1):66-70. PubMed PMID: 11298666.

2: Weyer G, Eul A, Milde K, Wierich W, Herrmann WM. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study. Pharmacopsychiatry. 2000 May;33(3):89-97. PubMed PMID: 10855459.

3: Siniatchkin M, Gerber WD, Vein A. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study. Funct Neurol. 1998 Jan-Mar;13(1):47-56. PubMed PMID: 9584874.

4: Hester TO, Theilman G, Green W, Jones RO. Cyclandelate in the management of tinnitus: a randomized, placebo-controlled study. Otolaryngol Head Neck Surg. 1998 Mar;118(3 Pt 1):329-32. PubMed PMID: 9527112.

5: Schellenberg R, Todorova A, Wedekind W, Schober F, Dimpfel W. Pathophysiology and psychopharmacology of dementia--a new study design. 2. Cyclandelate treatment--a placebo-controlled double-blind clinical trial. Neuropsychobiology. 1997;35(3):132-42. PubMed PMID: 9170118.

6: Diener HC, Föh M, Iaccarino C, Wessely P, Isler H, Strenge H, Fischer M, Wedekind W, Taneri Z. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group. Cephalalgia. 1996 Oct;16(6):441-7. PubMed PMID: 8902255.

7: Gerber WD, Schellenberg R, Thom M, Haufe C, Bölsche F, Wedekind W, Niederberger U, Soyka D. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study. Funct Neurol. 1995 Jan-Feb;10(1):27-35. PubMed PMID: 7649498.

8: Dimpfel W, Schober F, Wedekind W, Kleinbloesem C, Coors C. [Evidence of a pharmacokinetic-pharmacodynamic relationship between pharmaco-EEG in healthy subjects after administration of cyclandelate]. Arzneimittelforschung. 1994 Sep;44(9):999-1004. German. PubMed PMID: 7986255.

9: White DA, Heffron F, Knight D, Salter AM. The effects of two acylcoenzyme A: cholesterol acyltransferase (ACAT) inhibitors, cyclandelate and a non-hydrolysable ether analogue, benzyl3,3,5-trimethylcyclohexanol on low density lipoprotein metabolism in macrophages and hepatocytes. Biochem Pharmacol. 1994 Aug 30;48(5):915-22. PubMed PMID: 8093104.

10: Kitajima A, Yoshii K, Komatsu H, Ishimitsu S, Okada S. [The Cyclandelate Reference Standard (Control 931) of the National Institute of Health Sciences]. Eisei Shikenjo Hokoku. 1994;(112):185-7. Japanese. PubMed PMID: 8854927.